New frontiers in the design and synthesis of imaging probes for PET Oncology: Current challenges and future directions

Molecular Imaging and Biology

Volumn 14, Issue 6, 2012, Pages 653-666

  Smith, Graham ^a   Carroll, Laurence ^b   Aboagye, Eric O ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

18F FDG; Positron emission tomography; Probe development; Therapy monitoring

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; ARGINYLGLYCYLASPARTIC ACID; CARBON 4' METHYLTHIOTHYMIDINE C 11; DOCETAXEL; FLUCICLATIDE F 18; FLUORO HX4 F 18; FLUOROBENZYLTRIPHENYLPHOSPHONIUM F 18; FLUORODEOXYGLUCOSE F 18; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ZIRCONIUM BEVACIZUMAB ZR 89;

APOPTOSIS; CANCER DIAGNOSIS; CANCER GROWTH; CELL PROLIFERATION; DRUG ANALYSIS; DRUG HALF LIFE; DRUG UPTAKE; HUMAN; HYPOXIA; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR SCINTISCANNING; TUMOR VASCULARIZATION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; HUMANS; MOLECULAR IMAGING; MOLECULAR PROBES; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84870468843     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-012-0590-y     Document Type: Review

References (93)

1. Aboagye EO (2010) The future of imaging: Developing the tools for monitoring response to therapy in oncology: The 2009 Sir james MacKenzie davidson memorial lecture. Brit J Radiol 83(994):814-822
2. Vallabhajosula S (2007) (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: An overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 37(6):400-419
3. Fass L (2008) Imaging and cancer: A review. Mol Oncol 2(2):115-152
4. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674
5. Pal A, Balatoni JA, Mukhopadhyay U et al (2011) Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA -a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas. Mol Imaging Biol 13(5):853-861
6. Yeh HH, Ogawa K, Balatoni J et al (2011) Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci USA 108(4):1603-1608
7. Sharma R, Aboagye E (2011) Development of radiotracers for oncology -the interface with pharmacology. Brit J Pharmacol 163(8):1565-1585
8. Matthews PM, Rabiner EA, Passchier J, Gunn RN (2012) Positron emission tomography molecular imaging for drug development. Brit J Clin Pharmacol 73(2):175-186
9. Chopra A, Shan L, Eckelman WC, Leung K, Menkens AE (2011) Important parameters to consider for the characterization of PET and SPECT imaging probes. Nucl Med Biol 38(8):1079-1084
10. Haji-Saeid M, Pillai MRA, Ruth TJ, Schlyer DJ, Van den Winkel P, Vora MM(2009) Cyclotron produced radionuclides: physical characteristics and production methods. IAEA Technical Reports Series No. 468. Vienna
11. Disselhorst JA, Brom M, Laverman P et al (2010) Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. J Nucl Med 51(4):610-617
12. Brooks PC (1996) Role of integrins in angiogenesis. Eur J Cancer 32 (14):2423-2429
13. Dijkgraaf I, Yim C-B, Franssen G et al (2011) PET imaging of αvβ3 integrin expression in tumours with 68Ga-labelled mono-, di-and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging 38(1):128-137
14. Poethko T, Schottelius M, Thumshirn G et al (2004) Chemoselective pre-conjugate radiohalogenation of unprotected mono-and multimeric peptides via oxime formation. Radiochim Acta 92(4-6):317-327
15. Yan Y, Chen K, Yang M, Sun X, Liu S, Chen X (2011) A new 18Flabeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids 41(2):439-447
16. Glaser M, Morrison M, Solbakken M et al (2008) Radiosynthesis and biodistribution of cyclic RGD peptides conjugated with novel [18f] fluorinated aldehyde-containing prosthetic groups. Bioconj Chem 19 (4):951-957
17. Kenny LM, Coombes RC, Oulie I et al (2008) Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18FAH111585 in breast cancer patients. J Nucl Med 49(6):879-886
18. Battle MR, Goggi JL, Allen L, Barnett J, Morrison MS (2011) Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αvβ3-integrin and αvβ5-integrin imaging agent. J Nucl Med 52(3):424-430
19. Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, Wedge SR (2009) Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med 50(1):116-122
20. Solban N, Pål SK, Alok SK, Sung CK, Hasan T (2006) Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Res 66 (11):5633-5640
21. Nagengast WB, de Vries EG, Hospers GA et al (2007) In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48(8):1313-1319
22. Reed JC (2002) Apoptosis-based therapies. Nat Rev Drug Disc 1:111-121
23. Blankenberg FG (2008) Monitoring of treatment-induced apoptosis in oncology with PET and SPECT. Current Pharm Design 14 (28):2974-2982
24. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
25. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET Response Criteria in Solid Tumors. J Nucl Med 50:S122-S150
26. Li X, Link JM, Stekhova S et al (2008) Site-specific labeling of annexin V with F-18 for apoptosis imaging. Bioconj Chem 19(8):1684-1688
27. Wang F, Fang W, Zhang MR et al (2011) Evaluation of chemotherapy response in VX2 rabbit lung cancer with 18F-labeled C2A domain of synaptotagmin I. J Nucl Med 52(4):592-599
28. Reshef A, Shirvan A, Akselrod-Ballin A, Wall A, Ziv I (2010) Smallmolecule biomarkers for clinical PET imaging of apoptosis. J Nucl Med 51(6):837-840
29. Damianovich M, Ziv I, Heyman SN et al (2006) ApoSense: a novel technology for functional molecular imaging of cell death in models of acute renal tubular necrosis. Eur J Nucl Med Mol Imaging 33:281-291
30. Cohen A, Shirvan A, Levin G, Grimberg H, Reshef A, Ziv I (2009) From the Gla domain to a novel small-molecule detector of apoptosis. Cell Res.
31. Grimberg H, Levin G, Shirvan A et al (2009) Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis. Apoptosis 14:257-267
32. Hoglund J, Shirvan A, Antoni G et al (2011) 18F-ML-10, a PET tracer for apoptosis: First human study. J Nucl Med 52(5):720-725
33. Allen AM, Ben-Ami M, Reshef A, et al. (2012) Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with (18)F-ML-10. Eur J Nucl Med Mol Imaging
34. Chu W, Zhang J, Zeng C et al (2005) N-benzylisatin sulfonamide analogues as potent caspase-3 inhibitors: Synthesis, in vitro activity, and molecular modeling studies. J Med Chem 48:7637-7647
35. Kopka K, Faust A, Keul P et al (2006) 5-Pyrrolidinylsulfonyl isatins as a potential tool for the molecular imaging of caspases in apoptosis. J Med Chem 49:6704-6715
36. Smith G, Glaser M, Perumal M et al (2008) Design, synthesis and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide. J Med Chem 51:8057-8067
37. Chen DL, Zhou D, Chu W et al (2012) Radiolabeled isatin binding to caspase-3 activation induced by anti-Fas antibody. Nucl Med Biol 39 (1):137-144
38. Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO (2009) Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci USA 106(38):16375-16380
39. Nguyen QD, Challapalli A, Smith G, Fortt R, Aboagye EO (2012) Imaging apoptosis with positron emission tomography: 'Bench to bedside' development of the caspase-3/7 specific radiotracer [(18)F] ICMT-11. Eur J Cancer 48(4):432-440
40. Madar I, Ravert H, Nelkin B et al (2007) Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation. Eur J Nucl Med Mol Imaging 34 (12):2057-2065
41. Madar I, Bencherif B, Lever J et al (2007) Imaging delta-and muopioid receptors by PET in lung carcinoma patients. J Nucl Med 48 (2):207-213
42. Madar I, Huang Y, Ravert H et al (2009) Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18Ffluorobenzyl triphenyl phosphonium. J Nucl Med 50(5):774-780
43. Kim DY, Kim HJ, Yu KH, Min JJ (2012) Synthesis of [(18)F]-Labeled (6-Fluorohexyl)triphenylphosphonium cation as a potential agent for myocardial imaging using positron emission tomography. Bioconj Chem 23(3):431-437
44. Swed A, Eyal S, Madar I, Zohar-Kontante H, Weiss L, Hoffman A (2009) The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium. Mol Pharm 6(6):1883-1890
45. Mendichovszky I, Jackson A (2011) Imaging hypoxia in gliomas. Brit J Radiol 84(Spec No 2):S145-S158
46. Shetty D, Jeong JM, Shim H (2012) Stroma targeting nuclear imaging and radiopharmaceuticals. Int J Mol Imaging 2012:817682
47. Sun X, Niu G, Chan N, Shen B, Chen X (2011) Tumor hypoxia imaging. Mol Imaging Biol 13(3):399-410
48. Barthel H, Wilson H, Collingridge DR et al (2004) In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emmission tomography. Brit J Cancer 90:2232-2242
49. Dubois LJ, Lieuwes NG, Janssen MHM et al (2011) Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci USA 108(35):14620-14625
50. van Loon J, Janssen M, Öllers M et al (2010) PET imaging of hypoxia using [18F]HX4: A phase I trial. Eur J Nucl Med Mol Imaging 37 (9):1663-1668
51. Holland JP, Aigbirhio FI, Betts HM et al (2006) Functionalized bis (thiosemicarbazonato) complexes of zinc and copper: Synthetic platforms toward site-specific radiopharmaceuticals. Inorg Chem 46 (2):465-485
52. Bayly SR, King RC, Honess DJ et al (2008) In vitro and in vivo evaluations of a hydrophilic 64Cu-bis(thiosemicarbazonato)-glucose conjugate for hypoxia imaging. J Nucl Med 49(11):1862-1868
53. Kersemans V, Cornelissen B, Hueting R et al (2011) Hypoxia imaging using PET and SPECT: Hypoxia imaging using PET and SPECT: The effects of anesthetic and carrier gas on [64Cu]-ATSM, [99Tc]-HL91 and [18F]-FMISO tumor hypoxia accumulation. PLoS One 6(11):e25911
54. Toyohara J, Fujibayashi Y (2003) Trends in nucleoside tracers for PET imaging of cell proliferation. Nucl Med Biol 30(7):681-685
55. Bading JR, Shields AF (2008) Imaging of cell proliferation: Status and prospects. J Nucl Med 49(Suppl 2):64S-80S
56. Paproski RJ, Wuest M, Jans HS et al (2010) Biodistribution and uptake of 3′-deoxy-3′-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model. J Nucl Med 51(9):1447-1455
57. Cobben DC, Elsinga PH, Hoekstra HJ et al (2004) Is 18F-3′-fluoro- 3′-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med 45(10):1677-1682
58. Buck AK, Halter G, Schirrmeister H et al (2003) Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44 (9):1426-1431
59. Kenny LM, Contractor KB, Stebbing J et al (2009) Altered tissue 3′-deoxy-3′-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin Cancer Res 15(21):6649-6657
60. Leyton J, Alao JP, Da Costa M et al (2006) In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Cancer Res 66 (15):7621-7629
61. Rueger MA, Ameli M, Li H et al (2011) [18F]FLT PET for noninvasive monitoring of early response to gene therapy in experimental gliomas. Mol Imaging Biol 13(3):547-557
62. Soloviev D, Lewis D, Honess D, Aboagye E (2012) [(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer 48(4):416-424
63. Perumal M, Pillai RG, Barthel H et al (2006) Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 66(17):8558-8564
64. Pillai RG, Forster M, Perumal M et al (2008) Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945. Cancer Res 68(10):3827-3834
65. Toyohara J, Hayashi A, Sato M et al (2002) Rationale of 5-125I-iodo-4′-thio-2′-deoxyuridine as a potential iodinated proliferation marker. J Nucl Med 43:1218-1226
66. Toyohara J, Kumata K, Fukushi K, Irie T, Suzuki K (2006) Evaluation of 4′-[methyl-14C]thiothymidine for in vivo DNA synthesis imaging. J Nucl Med 47:1717-1722
67. Toyohara J, Nariai T, Sakata M et al (2011) Whole-body distribution and brain tumor imaging with (11)C-4DST: a pilot study. J Nucl Med 52(8):1322-1328
68. Mukhopadhyay U, Soghomonyan S, Yeh HH et al (2008) N(3)-substituted thymidine analogues V: Synthesis and preliminary PET imaging of N(3)-[(18)F]fluoroethyl thymidine and N(3)-[(18)F]fluoropropyl thymidine. Nucl Med Biol 35(6):697-705
69. Smith G, Sala R, Carroll L, et al. (2012) Synthesis and evaluation of nucleoside radiotracers for imaging proliferation. Nucl Med Biol
70. Cai L, Lu S, Pike VW (2008) Chemistry with [18F]Fluoride Ion. Eur J Org Chem 17:2853-2873
71. Glaser M, Årstad E (2007) "Click labeling" with 2-[18F]fluoroethylazide for positron emission tomography. Bioconj Chem 18:989-993
72. Barletta J, Karimi F, Långstrom B (2006) Synthesis of [11C-carbonyl] hydroxyureas by a rhodium mediated carbonylation reaction using [11C] carbon monoxide. J Labelled Compd Radiopharm 49:429-436
73. Rahman O, Kihlberg T, Langstrom B (2003) Aryl triflates and [11C]/ (13C)carbon monoxide in the synthesis of 11C-/13C-amides. J Org Chem 68(9):3558-3562
74. Rahman O, Kihlberg T, Langstrom B (2004) Synthesis of [11C]/ (13C)amines via carbonylation followed by reductive amination. Org Biomol Chem 2(11):1612-1616
75. Baskin JM, Prescher JA, Laughlin ST et al (2007) Copper-free click chemistry for dynamic in vivo imaging. Proc Natl Acad Sci USA 104 (43):16793-16797
76. Bouvet V, Wuest M, Wuest F (2011) Copper-free click chemistry with the short-lived positron emitter fluorine-18. Org Biomol Chem 9 (21):7393-7399
77. Campbell-Verduyn LS, Mirfeizi L, Schoonen AK, Dierckx RA, Elsinga PH, Feringa BL (2011) Strain-promoted copper-free "click" chemistry for 18F radiolabeling of bombesin. Angew Chem Int Ed 50(47):11117-11120
78. Carpenter RD, Hausner SH, Sutcliffe JL (2011) Copper-free click for PET: Rapid 1,3-dipolar cycloadditions with a fluorine-18 cyclooctyne. ACS Med Chem Lett 2(12):885-889
79. Evans HL, Slade RL, Carroll L et al (2012) Copper-free click-a promising tool for pre-targeted PET imaging. Chem Commun 48 (7):991-993
80. Sletten EM, Bertozzi CR (2011) From mechanism to mouse: A tale of two bioorthogonal reactions. Acc Chem Res 44(9):666-676
81. Devaraj NK, Weissleder R (2011) Biomedical applications of tetrazine cycloadditions. Acc Chem Res 44(9):816-827
82. Selvaraj R, Liu S, Hassink M et al (2011) Tetrazine-trans-cyclooctene ligation for the rapid construction of integrin αvβ3 targeted PET tracer based on a cyclic RGD peptide. Bioorg Med Chem Lett 21(17):5011-5014
83. Keliher EJ, Reiner T, Turetsky A, Hilderbrand SA, Weissleder R (2011) High-yielding, two-step 18F labeling strategy for 18F-PARP1 inhibitors. ChemMedChem 6(3):424-427
84. Li Z, Cai H, Hassink M et al (2010) Tetrazine-trans-cyclooctene ligation for the rapid construction of 18F labeled probes. Chem Commun 46 (42):8043-8045
85. Pretze M, Große-Gehling P, Mamat C (2011) Cross-coupling reactions as valuable tool for the preparation of PET radiotracers. Molecules 16 (2):1129-1165
86. Watson DA, Su M, Teverovskiy G et al (2009) Formation of ArF from LPdAr(F): Catalytic conversion of aryl triflates to aryl fluorides. Science 325(5948):1661-1664
87. Lee E, Kamlet AS, Powers DC et al (2011) A fluoride-derived electrophilic late-stage fluorination reagent for PET imaging. Science 334(6056):639-642
88. Chopra A, Shan L, Eckelman WC et al (2012) Molecular imaging and contrast agent database (MICAD): Evolution and progress. Mol Imaging Biol 14(1):4-13
89. Boerman OC, Oyen WJ (2011) Immuno-PET of cancer: A revival of antibody imaging. J Nucl Med 52(8):1171-1172
90. Lapi SE, Welch MJ (2012) A historical perspective on the specific activity of radiopharmaceuticals: What have we learned in the 35 years of the ISRC? Nucl Med Biol 39(5):601-608
91. Fueger BJ, Czernin J, Hildebrandt I et al (2006) Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 47(6):999-1006
92. DeSouza N, Hoekstra OS, Nestle U et al (2012) EORTC imaging group. Eur J Cancer (Supplements) 10(1):82-87
93. Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: Extracting more information from medical images using advanced feature analysis. Eur J Cancer 48(4):441-446